Announcement

Collapse
No announcement yet.

Phase 1 Clinical Trial for NVG-291

Collapse
X
 
  • Filter
  • Time
  • Show
Clear All
new posts

    Phase 1 Clinical Trial for NVG-291


    NervGen Pharma Receives Ethics Approval to Initiate Phase 1 Clinical Trial for NVG-291

    About NVG-291

    NVG-291 is an inhibitor of PTP?, a promising target for reducing the clinical effects of nerve damage, either as a result of trauma, such as in the case of spinal cord injury, traumatic brain injury or stroke, or neurodegenerative diseases, such as multiple sclerosis or Alzheimer's disease. NervGen believes that inhibiting the activity of PTP? has the potential to promote nerve repair mechanisms such as nerve regeneration, remyelination and plasticity; promote autophagy, a cellular self-cleaning mechanism; and to promote a non-inflammatory phenotype in microglia cells, the innate immune cells of the brain.



    http://www.streetinsider.com/Newsfile/NervGen+Pharma+Receives+Ethics+Approval+to+Initiat e+Phase+1+Clinical+Trial+for+NVG-291/18259428.html via @Street_Insider #SpinalCordInjury #Paralysis #Disabled #Paraplegic #Quadriplegic

    "Some people say that, the longer you go the better it gets the more you get used to it, I'm actually finding the opposite is true."

    -Christopher Reeve on his Paralysis

    #2
    they’ve dosed 1st subject.

    https://www.nervgen.com/news-articles-media/

    Vancouver, Canada. May 6, 2021 – NervGen Pharma Corp. (TSX-V: NGEN) (OTCQX: NGENF) (“NervGen” or the “Company”), a clinical stage biotech company dedicated to developing innovative treatments for nerve damage and neurodegenerative diseases, is pleased to announce today that the first subject has been dosed with NVG-291 in the Company's Phase 1 clinical trial in healthy volunteers.

    “Dosing the first subject in the Phase 1 clinical trial represents an important and exciting milestone for NervGen, its founders, and particularly for patients with nerve damage that currently are in great need of new and novel therapies,” stated Paul Brennan, NervGen’s President and CEO. “NVG-291 has the potential to redefine how nerve damage is treated across multiple indications, whether caused by trauma or chronic disease. This is an important first step to bring this therapy to patients, and we look forward to completing our Phase 1 study and moving quickly to treating patients.”

    The Phase 1 study with NVG-291 is being conducted in Australia via Novotech (Australia) Pty Limited, a leading full-service contract research organization. The study, conducted in healthy subjects, is a two-part, triple-blind, randomized, placebo-controlled, first-in-human study. Part one of the study is the single ascending dose portion of the trial and will be conducted in females. Part two of the study is the multiple ascending dose portion of the trial and will be conducted in post-menopausal females. The primary objective of the trial is to evaluate the safety, tolerability, and pharmacokinetics of NVG-291.

    Upon completion of the multiple ascending dose portion of the trial in heathy subjects, NervGen intends to initiate a multi-dose Alzheimer’s disease patient cohort as a Phase 1b program. Concurrently, the Company also plans to initiate Phase 2 trials in spinal cord injury and multiple sclerosis with each of these trials planned to start in 2022.

    Comment


      #3
      Isn't the phase 1 trial just testing on someone in normal health for safety.

      I take it phase 2 for SCI will be for acute injuries, there still isn't any evidence of it working on chronic injuries is there?

      Comment


        #4
        FYI - Jerry Silver discussing Nervgen
        https://www.youtube.com/watch?v=ib7RaBlg63g

        He says he's working on applying the tech to chronics at the time of the interview...Dec 2020.

        Comment

        Working...
        X